Pacylex Pharmaceuticals

05/26/2026

Delighted to have BioTuesdays share the Pacylex story - an oral first-in-class cancer medicine pioneering a new treatment category.

Closely held Pacylex Pharmaceuticals is developing a first-in-class oral cancer therapy with a novel, broad mechanism of action designed for refractory cancers as both a monotherapy and a future combination therapy.

05/06/2026

Pacylex was named to ScaleUp Canada's Edmonton50. These are Edmonton based startups with the following characteristics:

Canada-made innovation with high potential for global commercialization and export

Positive impact on the world towards environment, food security, health outcomes etc.

High potential for advancing and strengthening the local economy

Edmonton 50Canada’s most scalable startups The definitive investor showcase of the most scalable Edmonton startups! The goal is to highlight Edmonton region’s thriving innovation economy at a global stage, and raise $100 million in capital for region’s startups.These are Edmonton based startup...

04/24/2026

Pacylex was featured in a Nature Cancer article on new payloads for ADCs:
"Pacylex, too, is now exploring zelenirstat as an ADC payload, encouraged by preclinical data reported in November 2025 suggesting that the targeted approach could boost potency as much as 1,000-fold, enabling much lower effective doses."
- New payloads drive next-gen antibody–drug conjugates - Nature Cancer April 23, 2026

As tumor resistance to ADCs grows, new payloads are being investigated — from decades-old agents to newer drug classes such as immunotherapies and radioligands.

01/19/2026

What is a microsummit you ask? Come and find out as we present the key elements of Pacylex's novel ADC payload programs in under 3 minutes.

01/11/2026

Hope to see you at JP Morgan in San Francisco this coming week.

11/04/2025

At our poster in San Diego showing that Pacylex’s lead drug works great on ADCs, (antibody drug conjugates).

11/04/2025

Delighted to report the first positive ADC data using Pacylex's zelenirstat as a payload, being presented today at the World ADC Congress in San Diego. ADCs with zelenirstat were 20->1,000 fold more potent against prostate and breast cancer cell lines than zelenirstat alone including a breast cancer line resistant to most ADCs.
https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-and-heidelberg-pharma-present-zelenirstat-antibody-drug-conjugate-data-at-the-16th-annual-world-adc?_gl=1*1hxfm9e*_gcl_au*MzAwNzk1NDg0LjE3NTU0NTcyMzQuMTcyNDM5NjU5Ni4xNzYyMjI4MjYyLjE3NjIyMjgyNzQ.

Edmonton, Alberta, Canada and Heidelberg Pharma, Ladenburg, Germany, November 4, 2025. Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company and world leader in developing N-myristoyltransferase inhibitors (NMTis) for cancer. Heidelberg Pharma AG (FSE: HPHA) is a clinical...

06/10/2025

Once again we head to BIO to meet with partners and seek new investors and partners for our oral zelenirstat in promising clinical trials in acute myeloid leukemia patients and our NMT inhibitor class of new ADC payloads.

Edmonton, Alberta, Canada June 10, 2025. Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company and world leader in N-myristoyltransferase inhibitors (NMTis) for cancer. Oral zelenirstat is a proprietary, potent, NMTi in clinical trials as a first-in-class treatment for he...

05/05/2025

AACR poster on zelenirstat from the lab of our CSO, Dr. Luc Berthiaume, with his grad student Rony Pain presenting.

05/05/2025

Headed to Boston to present our molecules as a new class of payloads for antibody drug conjugates (ADCs).